Affordability and access to the Pharmaceutical Benefits Scheme

Parliament house flag post

Affordability and access to the Pharmaceutical Benefits Scheme

Posted 28/09/2011 by Rebecca de Boer

Expenditure on the Pharmaceutical Benefits Scheme (PBS) grew by 9.3 per cent last year (to 30 June 2010). Growth in PBS expenditure (and other health care programs) and the subsequent pressure on growth in spending was noted in paper recently released by Senator Wong as background to the upcoming tax forum. Yet it is not only government that is feeling the financial pain. A recent study found that expenditure by consumers on prescription medicines trebled between 1991 and 2007. The Government has attempted to rein in PBS spending through the Memorandum of Understanding (MOU) it signed with Medicines Australia and, controversially, the deferral of the listing of some medicines on the PBS.

Affordability of the PBS is only one of a number of PBS-related policy challenges facing the Government. The comparative high cost of generic medicines in Australia means that the Government is not making savings in the magnitude of other countries when pharmaceutical patents expire. Patent protection ensures a monopoly on manufacture and supply, resulting in such drugs commanding higher prices. Both of these unresolved challenges: the high out-of-pocket cost for pharmaceuticals and the (comparatively) high cost of generic medicines were recently canvassed in the latest edition of the Australian Health Review.

Kemp et al compared private expenditure on prescription pharmaceuticals in Australia with 15 other OCED countries. Private expenditure is the co-payment amount (currently $34.20 for general patients, $5.60 for concession card holders) plus any additional payments like brand premiums. They found that private expenditure on prescription pharmaceuticals in Australia trebled between 1991 and 2007. This does not include spending on pharmaceuticals that might be under the co-payments or over-the-counter medications such as pain killers or topical creams. Of the countries studied, Australia ranked 6th highest for private prescription expenditure.

This finding supports an earlier (international) survey that reported that Australians are skipping medications due to cost. A recent Newspoll suggested that around 13 per cent of Australians had delayed buying a prescription drug because of cost. The Council of Australian Governments (COAG) Reform Council National Healthcare Agreement Performance Report for 2009-10 also found that one in ten Australians over the age of 15 were foregoing prescription medication due to cost (p. 44). This raises important questions about timely and affordable access to PBS medicines, one the stated objectives of the National Medicines Policy. It also raises questions about whether the changes to PBS implemented in 2007 designed to generate savings have made medicines more affordable to patients and government alike.

The cost of generic medicines has long been of concern to government. The Government’s most recent attempt to address this was the MOU signed with Medicines Australia. It further extends the arrangements introduced in 2007 and imposes statutory price reductions to generic medicines (most of which have already taken effect) and price reductions as a result of price disclosure. For further analysis see here.

Spinks and Richardson demonstrated that Australia pays significantly higher for many of its pharmaceuticals, especially generics, ‘than is necessary’. Many pharmaceutical patents have expired or are about to expire. This means that pharmaceuticals previously protected by patent are subject to competition as generic products enter the market. Generic products contain the same active ingredient as the original version and must meet safety and quality standards. In other countries, the introduction of generic medicines has usually resulted in significant price reductions and savings to government (and consumers).

Widespread change to the pricing of generic medicines is proposed by Spinks and Richardson. They contend that current framework is largely administrative in nature, resulting in higher prices (despite the statutory price reductions and price disclosure arrangements negotiated as part of the MOU). Other countries have successfully negotiated significant price reductions for generic medicines. The authors argue that Australia should take note of these price arrangements and adopt a more competitive approach to the pricing of generic medicines.

Stakeholder groups and the Parliament, justifiably, have been concerned with the deferral of medicines on the PBS. A major source of contention with the Government’s policy was that medicines would not be listed on the PBS ‘until circumstances permit’ (widely interpreted as when the Budget returned to surplus) and that medicines would only be listed if savings could be found to offset the fiscal impact. This was considered by some to undermine the clinical and economic evaluation conducted by the independent Pharmaceutical Benefits Advisory Committee (PBAC) as part of the listing process. What further fuelled debate was the decision that each positive recommendation of the PBAC required Cabinet consideration before it could be listed on the PBS. Previously, only drugs which cost more than $10 million in any of the first four years of listing required Cabinet consideration. See here for further explanation.

A Senate Inquiry to investigate the impact of deferral of PBS medicines and associated administrative processes (namely the ‘criteria’ to determine the medicines to be deferred) has been completed. The Report recommended that the Government revert to previous PBS listing processes. It called on the Government to reinstate the $10 million Cabinet threshold and argued that listing of medicines on the PBS should not be dependent on finding savings in other areas of health. The Government Senators minority report argued that the decision to defer medicines on the PBS was a ‘difficult decision on the ground of financial responsibility’. The Australian Greens, noted that savings from the PBS could be achieved by alternative methods of pricing generic medicines rather than the deferral of PBS medicines.

Around the time the report was tabled, Prime Minister Gillard promised a ‘solution’ to the deferral of medicines on the PBS would be achieved by the end of September. To date, the Government has not given any indication as to what their policy response might be. In her keynote address to a conference jointly organised by the Department of Health and Ageing and Medicines Australia, Minister Roxon was reported as being committed to work with industry and consumers to develop a 'fair and efficient' process for deferrals.

‘Value for money’ and the ‘right price’ is a perennial issue in Australian pharmaceutical policy. Principles of economic evaluation have served Australia well but perhaps the time is right for a new approach for the pricing of generic medicines to be considered. Although it may be too early to tell, it is doubtful that the Government’s current approach will offer savings in the magnitude achieved by other countries. The deferral of medicines on the PBS is, at best, a short term solution to rising expenditure on the PBS. Even if the Government is able to develop a solution by the end of September, the underlying policy challenges of affordability and the price of generic medicines will remain.

Thank you for your comment. If it does not require moderation, it will appear shortly.
Facebook LinkedIn Twitter Add | Email Print


Flagpost is a blog on current issues of interest to members of the Australian Parliament

Parliamentary Library Logo showing Information Analysis & Advice




refugees asylum immigration Australian foreign policy Parliament elections climate change social security women welfare reform taxation Indigenous Australians Australian Defence Force welfare policy school education higher education private health insurance health financing emissions trading Middle East Senate Australian Bureau of Statistics employment people trafficking Asia statistics illicit drugs gambling health reform federal election 2010 Australian Public Service income management Medicare disability Sport United Nations environment industrial relations constitution transport politics criminal law Afghanistan health forced labour food public service reform aged care aid Australian Sports Anti-Doping Agency World Anti-Doping Agency United States federal budget Carbon Pricing Mechanism dental health international relations governance regulation Fair Work Act voting law enforcement electoral reform OECD Australian Electoral Commission WADA child protection poker machines Australia in the Asian Century steroids National Disability Insurance Scheme detention 43rd Parliament slavery health system leadership domestic violence parliamentary procedure International Women's Day accountability defence capability multiculturalism ASADA Australian Federal Police labour force people smuggling debt New Zealand Australian Crime Commission pharmaceutical benefits scheme political parties coal seam gas Human rights crime China Census election results UK Parliament Papua New Guinea banking corruption pensions children's health Aviation federal election 2013 foreign debt gross debt net debt Senators and Members ALP Newstart Parenting Payment Youth Allowance sea farers United Kingdom energy food labelling Australian economy violence against women vocational education and training military history by-election High Court skilled migration mental health Federal Court terrorist groups science social media Higher Education Loan Program HECS federal state relations youth paid parental leave same sex relationships customs planning doping health risks Gonski Review of Funding for Schooling sex slavery Special Rapporteur Northern Territory Emergency Response social policy ANZUS Rural and regional trade unions Foreign affairs election timetable Indigenous royal commission Productivity firearms public policy Population ADRV terrorism transparency research and development welfare ASIO intelligence community Australian Security Intelligence Organisation carbon tax mining employer employee renewable energy regional unemployment fishing European Union family assistance United Nations Security Council forestry Drugs welfare systems Indonesia children Constitutional reform local government codes of conduct terrorist financing homelessness Parliamentary remuneration money laundering Trafficking in Persons Report social inclusion paternalism environmental law US presidential election nutrition ODA Defence sitting days electoral divisions Southeast Asia administrative law universities TAFE Ireland citizenship asylum seekers early childhood education Canada Financial sector national security fuel disability employment Tasmania integrity standards NATO Australian Secret Intelligence Service sexual abuse World Trade Organization Australia public health housing affordability bulk billing water health policy Governor-General US economy export liquefied natural gas foreign bribery question time speaker superannuation public housing expertise climate Intergovernmental Panel on Climate Change Department of Agriculture Fisheries and Forestry Pacific Islands reserved seats new psychoactive substances synthetic drugs UNODC carbon markets animal health middle class welfare constitutional recognition of local government referendum consumer laws PISA competition policy US politics language education baby bonus Leaders of the Opposition citizen engagement policymaking Australia Greens servitude Trafficking Protocol forced marriage alcohol entitlements ministries Hung Parliament social citizenship maritime Iran regional students school chaplains federal budget 2011-12 salary Medicare Locals primary care Building the Education Revolution Turkey Syria marine pollution sustainability prisons police deaths in custody electoral margins electoral pendulum electoral redistribution redistribution NSW redistribution WA redistribution ACT electoral boundaries ASEAN Sustainable Development Goals Double dissolution Senators safety vehicles MYEFO Pathology tertiary education Taiwan Xi Ma meeting family violence government financial advisers financial planners Financial System Inquiry Murray Inquiry China; Economic policy; Southeast Asia; Africa housing Speaker; House of Representatives; Parliament High Court; Indigenous; Indigenous Australians; Native Title ACT Indigenous education Norfolk Island External Territories emissions reduction fund; climate change child care funding refugees immigration asylum procurement Indigenous health e-voting internet voting nsw state elections 44th Parliament 2015 ABS Age Pension Death penalty capital punishment execution Bali nine Bali bombings Trade EU China soft power education Fiji India Disability Support Pension Antarctica Diplomacy by-elections state and territories Bills anti-corruption fraud bribery corporate ownership whistleblower G20 economic reform innovation Members of Parliament Scottish referendum Middle East; national security; terrorism social services Criminal Code Amendment (Misrepresentation of Age to a Minor) Bill 2013 online grooming sexual assault of minors ACT Assembly smoking plain packaging tobacco cigarettes Asia; Japan; international relations Work Health and Safety Migration; asylum seekers; regional processing China; United States; international relations fiscal policy Racial Discrimination Act; social policy; human rights; indigenous Australians Foreign policy Israel Palestine asylum refugees immigration political finance donations foreign aid Economics efficiency human rights; Racial Discrimination Act employment law bullying Animal law; food copyright Australian Law Reform Commission industry peace keeping contracts workplace policies same-sex marriage disorderly conduct retirement Parliament House standing orders prime ministers First speech defence budget submarines workers Somalia GDP world heritage political engagement leave loading Trade; tariffs; safeguards; Anti-dumping public interest disclosure whistleblowing Productivity Commission limitation period cancer gene patents genetic testing suspension of standing and sessional orders live exports infant mortality honorary citizen railways disciplinary tribunals standard of proof World Health Organisation arts international students skilled graduate visas temporary employment visas apologies roads Italy national heritage NHMRC anti-dumping Rent Assistance obesity evidence law sacrament of confession international days DFAT UN General Assembly deregulation Regulation Impact Statements small business Breaker Morant regional engagement social determinants of health abortion Members suspension workplace health and safety marine reserves hearing Victoria astronomy resources sector YMCA youth parliament Korea rebate Australian Greens presidential nomination Racial Discrimination Act political parties preselection solar hot water Financial Action Taskforce Horn of Africa peacekeeping piracy Great Barrier Reef Stronger futures political financing political education Social Inclusion Board early childhood National Quality Framework for Early Childhood Education and Care Murray-Darling Basin sanctions Norway hospitals republic President Barack Obama Presidential visits qantas counselling Korean peninsula Work Choices biosecurity hendra federalism federation preselection therapeutic goods Therapeutic Goods Administration plebiscites computer games pests suicide nuclear COAG Ministerial Councils floods ADHD stimulant medication advertising electricity extradition conscience votes poverty preventative health rural health coastal erosion Parliamentary Budget Office work-life balance

Show all
Show less
Back to top